AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal.

This time, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere, which won FDA accelerated approval about a year ago.